Recent evidence suggests that combining blood p-tau 217 and Aβ42/Aβ40 levels could be useful for the early identification of symptomatic AD cases [6] and, potentially, for subject selection in primary prevention trials [7]. Here, MAPT is linked to Alzheimer disease.